Amgen Licenses Molecule for the Treatment of Chronic and Neuropathic Pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc. (Business Wire via Yahoo! Finance)

THOUSAND OAKS, Calif.----Amgen today announced that it has licensed a clinical stage molecule for the treatment of chronic and neuropathic pain to Ortho-McNeil-Janssen Pharmaceuticals, Inc. , a Johnson & Johnson company.

[News Source]